CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenue:
Total revenue	$ 20,968	$ 41,867	$ 23,028
Operating expenses:
Cost of goods sold	6,174	7,266
Research and development	108,510	91,879	82,701
General and administrative	27,779	30,257	29,410
Total operating expenses	142,463	129,402	112,111
Operating loss	(121,495)	(87,535)	(89,083)
Other income, net	3,586	2,061	642
Non-cash interest expense on liability related to sales of future royalties and milestones	(604)
Net loss	$ (118,513)	$ (85,474)	$ (88,441)
Net loss per share:
Basic	$ (2.19)	$ (1.59)	$ (1.74)
Diluted	$ (2.19)	$ (1.59)	$ (1.74)
Weighted average shares:
Basic	54,149,059	53,653,564	50,718,765
Diluted	54,149,059	53,653,564	50,718,765
Other comprehensive income (loss), net of tax of $0:
Change in unrealized gains (losses) on available-for-sale marketable securities	$ 1,412	$ (1,314)	$ (431)
Total comprehensive loss	(117,101)	(86,788)	(88,872)
Collaborative revenue
Revenue:
Total revenue	12,936	16,572	706
Commercial supply revenue
Revenue:
Total revenue	5,843	10,223	701
License and milestone fees
Revenue:
Total revenue	910	15,000	21,223
Royalty revenue
Revenue:
Total revenue	415	$ 72
Clinical compound revenue
Revenue:
Total revenue	165		$ 398
Other revenue
Revenue:
Total revenue	$ 699